Oral cancer treatment: Developments in chemotherapy and beyond

British Journal of Cancer

Volumn 87, Issue 9, 2002, Pages 933-937

  O'neill V J ^a   Twelves, C J ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Drug development; Oral chemotherpay

Indexed keywords

2' CYANO 2' DEOXY 4 N PALMITOYLCYTARABINE; 5 ETHYNYLURACIL; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; BMS 275183; BMS 294662; CAMPTOTHECIN DERIVATIVE; CAPECITABINE; CEP 701; CETUXIMAB; CP 461; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOTOXIC AGENT; DIFLOMOTECAN; ELACRIDAR; ERLOTINIB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IMATINIB; MIDOSTAURIN; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; SU 006668; TAS 102; TAXANE DERIVATIVE; TEGAFUR; TOPOTECAN; UFT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACNE; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CARDIOTOXICITY; CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG ACTIVITY; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG TARGETING; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; LUNG SMALL CELL CANCER; MOLECULAR MECHANICS; MOUTH CANCER; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RASH; REVIEW; TOXICITY; VOMITING;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; DRUG DESIGN; HUMANS; NEOPLASMS;

EID: 0037152667     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600591     Document Type: Review

References (24)

1. Borner MM, Dietrich D, Stupp R, Morant R, Honegger H, Wernli M, Herrmann R, Pestalozzi BC, Saletti P, Hanselmann S, Muller S, Brauchli P, Castiglione-Gertsch M, Goldhirsch A, Roth AD (2002) Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol 20:(7): 1759-1766
2. Baselga J (2001) The EGFR as a target for anticancer therapy-focus on cetuximab. Eur J Cancer 37:(Suppl 4:): S16-S22
3. Baselga J, Herbst R, LoRusso P, Rischin D, Ranson M, Plummer R, Raymond E, Maddox A-M, Kaye SB, Kieback D G, Harris A, Ochs J (2000) Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumor types: Evidence of activity and good tolerability. Proc Am Soc Clin Oncol 19: 177
4. Cassidy J, Twelves C, Cameron D, Steward W, O'Byrne K, Jodrell D, Banken L, Goggin T, Jones D, Roos B, Bush E, Weidekamm E, Reigner B (1999) Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients. Cancer Chemother Pharmacol 44:(6): 453-460
5. DeMario MD, Ratain MJ (1998) Oral chemotherapy: Rationale and future directions. J Clin Oncol 16:(7): 2557-2567
6. Guengerich FP (1992) Characterisation of human P450 enzymes. FASEB J 6: 745-748
7. Kantarjian HM, Talpaz M (2001) Imatinib mesylate: Clinical results in Philadelphia chromosome-positive leukemias. Semin Oncol 28:(5 Suppl 17): 9-18
8. Lamont EB, Schilsky RI (1999) The oral fluoropyrimidines in cancer chemotherapy. Clin Cancer Res 5: 2289-2296
9. Lebovits AH, Strainn JJ, Schleifer SJ (1990) Patient non compliance with self-administered chemotherapy. Cancer 65: 17-22
10. Lee CR, Nicholson PW, Ledermann JA, Rustin GJ (1996) Patient compliance with prolonged oral altretamine treatment in relapsed ovarian cancer. Eur J Gynaecol Oncol 17:(2): 99-103
11. Lee CR, Nicholson PW, Souhami RL, Deshmukh AA (1992) Patient compliance with oral chemotherapy as assessed by a novel electronic technique. J Clin Oncol 10:(6): 1007-1013
12. Lee CR, Nicholson PW, Souhami RL, Slevin ML, Hall MR, Deshmukh AA (1993) Patient compliance with prolonged low-dose oral etoposide for small cell lung cancer. Br J Cancer 67:(3): 630-634
13. Liu G, Franssen E, Fitch M, Warner E (1997) Patient preference for oral versus intravenous palliative chemotherapy. J Clin Oncol 15: 110-115
14. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, Twelves C, Van Hazel G, Verma S, Leonard R (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 20(12): 2812-2823
15. Payne SA (1992) A study of quality of life in cancer patients receiving palliative chemotherapy. Soc Sci Med 35:(12): 1505-1509
16. Perez-Soler R, Chachoua A, Huberman M, Karp D, Rigas J, Hammond L, Rowinsky E, Preston G, Ferrante KJ, Allen LF, Nadler P, Bonomi P (2001) A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients with advancecd, EGFR-expressing, non-small cell lung cancer. Proc ASCO 20: 310
17. Polizzi D, Pratesi G, Monestiroli S, Tortoreto M, Zunino F, Bombardelli E, Riva A, Morazzoni P, Colombo T, d'Incalci M, Zucchetti M (2000) Oral efficacy and bioavailability of a novel taxane. Clin Cancer Res 6:(5): 2070-2074
18. Rose WC, Long BH, Fairchild CR, Lee FY, Kadow JF (2001) Preclinical pharmacology of BMS-275183, an orally active taxane. Clin Cancer Res 7:(7): 2016-2021
19. Rajagonopalan S, Hanson-Painton O, Cooper DR (2000) Protein kinases as therapeutic targets. Pharma Res 17:(11): 1345
20. Senzer NN, Soulieres D, Siu L, Agarwala S, Vokes E, Hidalgo M, Silberman S, Allen L, Ferrante K, Fishers D, Marsolais C, Nadler P (2001) Phase 2 elevation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck. Proc ASCO 20: 2
21. Sullivan SD, Mozaffari E, Johnson ES, Wolitz R, Follansbee SE (1996) An economic evaluation of oral compared with intravenoud ganciclovir for maintenance treatment of newly diagnosed cytomegalovirus inj AIDS patients. Clin Therapeut 18: 546-558
22. Twelves C, Boyer M, Findlay M, Cassidy J, Weitzel C, Barker C, Osterwalder B, Jamieson C, Hieke K; The Xeloda Colorectal Cancer Study Group (2001) Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Eur J Cancer 37:(5): 597-604
23. van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M, Silberman S, Nielsen OS; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (2001) Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358:(9291): 1421-1423
24. von Pawel J, Gatzemeier U, Pujol JL, Moreau L, Bildat S, Ranson M, Richardson G, Steppert C, Riviere A, Camlett I, Lane S, Ross G (2001) Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol 19:(6): 1743-1749